Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with a number of people in the Alzheimer disease field with varying and nuanced opinions on this decision to better understand not only what this approval means for the clinical care of patients, but what the downstream effects of it may be. Those individuals, in order of appearance, are:
- Marwan Sabbagh, MD, director, Cleveland Clinic Lou Ruvo Center for Brain Health, and investigator in the aducanumab trials
- Anton P. Porsteinsson, MD, director, Alzheimer's Disease Care, Research and Education Program, University of Rochester School of Medicine and Dentistry, and investigator in the aducanumab trials
- David Knopman, MD, professor of neurology, Mayo Clinic, and investigator in the aducanumab trials
- Lon Schneider, MD, MS, professor of Psychiatry and the Behavioral Sciences, and Della Martin Chair in Psychiatry and Neuroscience, University of Southern California Keck School of Medicine
- Robert Howard, MD, MRCPsych, Professor of Old Age Psychiatry, Faculty of Brain Sciences, University College London
- Ian Kremer, JD, executive director, LEAD Coalition
- Douglas Scharre, MD, neurologist and director, Division of Cognitive Neurology, Ohio State Wexner Medical Center
Thanks for listening to the
NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit
neurologylive.com.
For more insight and
NeurologyLive coverage of aducanumab,
click here.